Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Peptic Ulcer

  Free Subscription


Articles published in Digestion

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    December 2020
  1. YATAGAI N, Ueyama H, Ikemura M, Uchida R, et al
    Clinicopathological and Endoscopic Features of Raspberry-Shaped Gastric Cancer in Helicobacter pylori-Uninfected Patients.
    Digestion. 2020 Dec 15:1-8. doi: 10.1159/000511907.
    PubMed     Abstract available


    August 2020
  2. NORITA K, Asanuma K, Koike T, Okata T, et al
    Impaired Mucosal Integrity in Proximal Esophagus Is Involved in Development of Proton Pump Inhibitor-Refractory Nonerosive Reflux Disease.
    Digestion. 2020 Aug 12:1-11. doi: 10.1159/000508661.
    PubMed     Abstract available


    February 2020
  3. MATSUNAGA T, Endo H, Takamori A, Shimada F, et al
    Lifestyle- and Comorbidity-Related Risk Factors Associated with Prescription of Gastric Acid Secretion Inhibitors to Japanese Patients Who Were Helicobacter pylori Negative and Had No Upper Gastrointestinal Lesions.
    Digestion. 2020 Feb 25:1-9. doi: 10.1159/000506153.
    PubMed     Abstract available


  4. LIN L, Cui B, Deng Y, Jiang X, et al
    The Efficacy of Proton Pump Inhibitor in Cirrhotics with Variceal Bleeding: A Systemic Review and Meta-Analysis.
    Digestion. 2020 Feb 21:1-11. doi: 10.1159/000505059.
    PubMed     Abstract available


  5. ABE Y, Koike T, Saito M, Okata T, et al
    The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Digestion. 2020 Feb 14:1-9. doi: 10.1159/000506152.
    PubMed     Abstract available


    January 2020
  6. SHINOZAKI S, Kobayashi Y, Osawa H, Sakamoto H, et al
    Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Digestion. 2020 Jan 8:1-7. doi: 10.1159/000504939.
    PubMed     Abstract available


  7. MIZUNO H, Nishino M, Yamada K, Kamiyamamoto S, et al
    Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
    Digestion. 2020;101:411-421.
    PubMed     Abstract available


    December 2019
  8. HOJO M, Nagahara A, Hahm KB, Iwakiri R, et al
    Management of Gastroesophageal Reflux Disease in Asian Countries: Results of a Questionnaire Survey.
    Digestion. 2019 Dec 4:1-14. doi: 10.1159/000504749.
    PubMed     Abstract available


    November 2019
  9. NAKATA R, Nagami Y, Hashimoto A, Sakai T, et al
    Successful Eradication of Helicobacter pylori Could Prevent Metachronous Gastric Cancer: A Propensity Matching Analysis.
    Digestion. 2019 Nov 1:1-10. doi: 10.1159/000504132.
    PubMed     Abstract available


    October 2019
  10. HAMADA S, Ihara E, Ikeda H, Muta K, et al
    Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Digestion. 2019 Oct 2:1-8. doi: 10.1159/000503340.
    PubMed     Abstract available


    September 2019
  11. UENO T, Suzuki H, Hirose M, Shida T, et al
    Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults.
    Digestion. 2019 Sep 24:1-6. doi: 10.1159/000502574.
    PubMed     Abstract available


  12. SAKAE H, Iwamuro M, Okamoto Y, Obayashi Y, et al
    Evaluation of the Usefulness and Convenience of the Kyoto Classification of Gastritis in the Endoscopic Diagnosis of the Helicobacter pylori Infection Status.
    Digestion. 2019 Sep 19:1-8. doi: 10.1159/000502573.
    PubMed     Abstract available


  13. KUSANO C, Gotoda T, Ikehara H, Suzuki S, et al
    The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students.
    Digestion. 2019 Sep 10:1-6. doi: 10.1159/000502900.
    PubMed     Abstract available


    August 2019
  14. FURUTA T, Yamade M, Kagami T, Uotani T, et al
    Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Digestion. 2019 Aug 21:1-9. doi: 10.1159/000502287.
    PubMed     Abstract available


  15. IINO C, Shimoyama T, Chinda D, Sakuraba H, et al
    Influence of Helicobacter pylori Infection and Atrophic Gastritis on the Gut Microbiota in a Japanese Population.
    Digestion. 2019 Aug 8:1-11. doi: 10.1159/000500634.
    PubMed     Abstract available


  16. MORI H, Suzuki H, Matsuzaki J, Masaoka T, et al
    10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Digestion. 2019 Aug 6:1-7. doi: 10.1159/000501610.
    PubMed     Abstract available


    July 2019
  17. ABE Y, Koike T, Saito M, Okata T, et al
    Influence of the pH Value of Refluxate and Proximal Extent on Heartburn Perception in Patients with Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease.
    Digestion. 2019 Jul 29:1-7. doi: 10.1159/000500133.
    PubMed     Abstract available


  18. ONO S, Dohi O, Yagi N, Sanomura Y, et al
    Accuracies of Endoscopic Diagnosis of Helicobacter pylori-Gastritis: Multicenter Prospective Study Using White Light Imaging and Linked Color Imaging.
    Digestion. 2019 Jul 23:1-7. doi: 10.1159/000501634.
    PubMed     Abstract available


  19. NISHIDA T, Tsujii Y, Okamoto A, Tomita R, et al
    A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Digestion. 2019 Jul 9:1-7. doi: 10.1159/000501608.
    PubMed     Abstract available


    June 2019
  20. DEGUCHI H, Uda A, Murakami K
    Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database.
    Digestion. 2019 Jun 19:1-9. doi: 10.1159/000500819.
    PubMed     Abstract available


  21. KNOOP RF, Petzold G, Amanzada A, Bremer SCB, et al
    Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions.
    Digestion. 2019 Jun 19:1-5. doi: 10.1159/000501270.
    PubMed     Abstract available


    May 2019
  22. GONG EJ, Kim DH, Ahn JY, Na HK, et al
    Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy.
    Digestion. 2019 May 8:1-8. doi: 10.1159/000499424.
    PubMed     Abstract available


    April 2019
  23. NABETA H, Shinozaki S, Abe Y, Koyanagi R, et al
    A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication.
    Digestion. 2019 Apr 16:1-7. doi: 10.1159/000499857.
    PubMed     Abstract available


  24. TSUDA M, Kato M, Ono S, Matsuda K, et al
    Changes of Dyspeptic Symptom after Successful Eradication in Helicobacter pylori-Associated Dyspepsia.
    Digestion. 2019 Apr 16:1-9. doi: 10.1159/000497432.
    PubMed     Abstract available


  25. INUI M, Ohwada S, Inui Y, Kondo Y, et al
    Evaluating the Accuracy of the Endoscopic ABC Classification System in Diagnosing Helicobacter pylori-Infected Gastritis.
    Digestion. 2019 Apr 12:1-10. doi: 10.1159/000498966.
    PubMed     Abstract available


    March 2019
  26. AKIYAMA J, Hosaka H, Kuribayashi S, Moriyasu S, et al
    Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Digestion. 2019 Mar 21:1-10. doi: 10.1159/000497775.
    PubMed     Abstract available


  27. OKUNO H, Suzuki S, Watanabe H, Kusano C, et al
    Histological Features of Gastric Mucosa Serologically Diagnosed as Gastric Atrophy without Helicobacter pylori Infection.
    Digestion. 2019 Mar 14:1-10. doi: 10.1159/000498940.
    PubMed     Abstract available


  28. SAKATA Y, Tsuruoka N, Takedomi H, Akutagawa T, et al
    A Study on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan.
    Digestion. 2019 Mar 6:1-8. doi: 10.1159/000498967.
    PubMed     Abstract available


    January 2019
  29. KAWAMURA Y, Funaki Y, Yoshimine T, Tamura Y, et al
    Characteristics and Predictive Factor of Helicobacter pylori-Associated Functional Dyspepsia in Japanese Patients.
    Digestion. 2019 Jan 10:1-9. doi: 10.1159/000496101.
    PubMed     Abstract available


  30. HATA K, Ito M, Boda T, Kotachi T, et al
    Gastric Cancer with Submucosal Invasion after Successful Helicobacter pylori Eradication: A Propensity Score-Matched Analysis of Patients with Annual Patient Endoscopic Survey.
    Digestion. 2019;99:59-65.
    PubMed     Abstract available


  31. OMORI J, Fujimori S, Kosugi Y, Yukiko K, et al
    Pilot Study Indicates Helicobacter pylori Infection May Induce Small Intestinal Mucosal Injury.
    Digestion. 2019;99:66-71.
    PubMed     Abstract available


  32. SAKATA Y, Tsuruoka N, Shimoda R, Yamamoto K, et al
    Comparison of Clinical Characteristics of Patients with Acute Esophageal Mucosal Lesion and those with Severe Reflux Esophagitis.
    Digestion. 2019;99:275-282.
    PubMed     Abstract available


    November 2018
  33. FUJIWARA Y, Hashimoto A, Uemura R, Sawada A, et al
    Optimal Biopsy Protocol to Evaluate Histological Effectiveness of Proton Pump Inhibitor Therapy in Patients with Eosinophilic Esophagitis.
    Digestion. 2018 Nov 8:1-8. doi: 10.1159/000494253.
    PubMed     Abstract available


    September 2018
  34. YOSHIMINE T, Funaki Y, Kawamura Y, Tamura Y, et al
    Convenient Method of Measuring Baseline Impedance for Distinguishing Patients with Functional Heartburn from those with Proton Pump Inhibitor-Resistant Endoscopic Negative Reflux Disease.
    Digestion. 2018 Sep 4:1-9. doi: 10.1159/000490790.
    PubMed     Abstract available


  35. TAKARA Y, Endo H, Nakano R, Kawachi K, et al
    Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Digestion. 2018 Sep 4:1-7. doi: 10.1159/000490889.
    PubMed     Abstract available


    July 2018
  36. MATSUDA R, Yamamichi N, Shimamoto T, Sumida H, et al
    Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients.
    Digestion. 2018;98:201-208.
    PubMed     Abstract available


    June 2018
  37. AKAZAWA Y, Ueyama H, Yao T, Komori H, et al
    Usefulness of Demarcation of Differentiated-Type Early Gastric Cancers after Helicobacter pylori Eradication by Magnifying Endoscopy with Narrow-Band Imaging.
    Digestion. 2018;98:175-184.
    PubMed     Abstract available


  38. BOLTIN D, Schmilovitz-Weiss H, Gingold-Belfer R, Leibovitzh H, et al
    Temporal Trends in Helicobacter pylori Eradication Success in a Test-and-Treat Population.
    Digestion. 2018;98:169-174.
    PubMed     Abstract available


    May 2018
  39. YAMADA A, Kaise M, Inoshita N, Toba T, et al
    Characterization of Helicobacter pylori-Naive Early Gastric Cancers.
    Digestion. 2018;98:127-134.
    PubMed     Abstract available


    April 2018
  40. TSUTSUMI K, Kusano C, Suzuki S, Gotoda T, et al
    Diagnostic Accuracy of Latex Agglutination Turbidimetric Immunoassay in Screening Adolescents for Helicobacter pylori Infection in Japan.
    Digestion. 2018;98:75-80.
    PubMed     Abstract available


  41. WINKELSETT L, Malfertheiner P, Wex T, Kandulski A, et al
    Mucosal Two-Step Pathogenesis in Gastroesophageal Reflux Disease: Repeated Weakly Acidic Stimulation and Activation of Protease-Activated Receptor-2 on Mucosal Interleukin-8 Secretion.
    Digestion. 2018;98:19-25.
    PubMed     Abstract available


  42. KOTACHI T, Ito M, Boda T, Kiso M, et al
    Clinical Significance of Reddish Depressed Lesions Observed in the Gastric Mucosa after Helicobacter pylori Eradication.
    Digestion. 2018;98:48-55.
    PubMed     Abstract available


    March 2018
  43. YAMADA S, Tomatsuri N, Kawakami T, Nakatsugawa Y, et al
    Helicobacter pylori Eradication Therapy Ameliorates Latent Digestive Symptoms in Chronic Atrophic Gastritis.
    Digestion. 2018;97:333-339.
    PubMed     Abstract available


  44. KODAMA M, Okimoto T, Mizukami K, Abe H, et al
    Endoscopic and Immunohistochemical Characteristics of Gastric Cancer with versus without Helicobacter Pylori Eradication.
    Digestion. 2018;97:288-297.
    PubMed     Abstract available


    February 2018
  45. MATSUURA S, Sakata Y, Tsuruoka N, Miyahara K, et al
    Outcomes of Patients Undergoing Endoscopic Hemostasis for the Upper Gastrointestinal Bleeding Were Not Influenced by the Timing of Hospital Emergency Visits: A Situation Prevailing in Japan.
    Digestion. 2018;97:260-266.
    PubMed     Abstract available


  46. KOJIMA Y, Takeuchi T, Sanomura M, Higashino K, et al
    Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
    Digestion. 2018;97:70-75.
    PubMed     Abstract available


  47. MATSUMURA T, Arai M, Ishigami H, Fujie M, et al
    Evaluation of Esophageal Mucosal Integrity in Patients with Gastroesophageal Reflux Disease.
    Digestion. 2018;97:31-37.
    PubMed     Abstract available


    January 2018
  48. OZAKI H, Harada S, Takeuchi T, Kawaguchi S, et al
    Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation
    Digestion. 2018;97:212-218.
    PubMed     Abstract available


  49. SAHARA S, Sugimoto M, Ichikawa H, Kagami T, et al
    Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial.
    Digestion. 2018;97:163-169.
    PubMed     Abstract available


  50. SHIOTANI A, Katsumata R, Gouda K, Fukushima S, et al
    Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors.
    Digestion. 2018;97:154-162.
    PubMed     Abstract available


  51. NAITO Y, Kashiwagi K, Takagi T, Andoh A, et al
    Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use.
    Digestion. 2018;97:195-204.
    PubMed     Abstract available


  52. YAMASAKI A, Yoshio T, Muramatsu Y, Horiuchi Y, et al
    Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
    Digestion. 2018;97:170-176.
    PubMed     Abstract available


  53. XU Y, Jia J, Xie C, Wu Y, et al
    Transient Receptor Potential Ankyrin 1 and Substance P Mediate the Development of Gastric Mucosal Lesions in a Water Immersion Restraint Stress Rat Model.
    Digestion. 2018;97:228-239.
    PubMed     Abstract available


  54. UMEZAWA M, Kawami N, Hoshino S, Hoshikawa Y, et al
    Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.
    Digestion. 2018;97:309-315.
    PubMed     Abstract available


    October 2017
  55. HORIUCHI Y, Fujisaki J, Ishizuka N, Omae M, et al
    Study on Clinical Factors Involved in Helicobacter pylori-Uninfected, Undifferentiated-Type Early Gastric Cancer.
    Digestion. 2017;96:213-219.
    PubMed     Abstract available


    August 2017
  56. CHINDA D, Shimoyama T, Iino C, Matsuzaka M, et al
    Decrease of Estradiol and Several Lifestyle Factors, but Not Helicobacter pylori Infection, Are Significant Risks for Osteopenia in Japanese Females.
    Digestion. 2017;96:103-109.
    PubMed     Abstract available


    July 2017
  57. OHTSU T, Takagi A, Uemura N, Inoue K, et al
    The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study.
    Digestion. 2017;96:92-102.
    PubMed     Abstract available


    June 2017
  58. YAMASHITA H, Kanamori A, Kano C, Hashimura H, et al
    The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Digestion. 2017;96:52-59.
    PubMed     Abstract available


  59. FUNAKI Y, Kaneko H, Kawamura Y, Yoshimine T, et al
    Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.
    Digestion. 2017;96:39-45.
    PubMed     Abstract available


  60. KOTACHI T, Ito M, Yoshihara M, Boda T, et al
    Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody: Relationship to Endoscopic Findings.
    Digestion. 2017;95:314-318.
    PubMed     Abstract available


  61. YAMAGUCHI D, Sakata Y, Yoshida H, Furukawa NE, et al
    Effectiveness of Endoscopic Hemostasis with Soft Coagulation for Non-Variceal Upper Gastrointestinal Bleeding over a 12-Year Period.
    Digestion. 2017;95:319-326.
    PubMed     Abstract available


    May 2017
  62. SUGIMOTO M, Sahara S, Ichikawa H, Sakao Y, et al
    Natural Course of Helicobacter pylori Infection in Japanese Hemodialysis Patients.
    Digestion. 2017;95:302-309.
    PubMed     Abstract available


  63. OKUYAMA M, Nakahara K, Iwakura N, Hasegawa T, et al
    Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Digestion. 2017;95:281-287.
    PubMed     Abstract available


    March 2017
  64. KISHIKAWA H, Kimura K, Ito A, Arahata K, et al
    Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
    Digestion. 2017;95:229-236.
    PubMed     Abstract available


  65. KASAMATSU S, Matsumura T, Ohta Y, Hamanaka S, et al
    The Effect of Ineffective Esophageal Motility on Gastroesophageal Reflux Disease.
    Digestion. 2017;95:221-228.
    PubMed     Abstract available


  66. MAJIMA A, Handa O, Naito Y, Dohi O, et al
    Early-Stage Gastric Cancer Can Be Found in Improved Atrophic Mucosa over Time from Successful Helicobacter pylori Eradication.
    Digestion. 2017;95:194-200.
    PubMed     Abstract available


    February 2017
  67. HOSHINO S, Kawami N, Takenouchi N, Umezawa M, et al
    Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Digestion. 2017;95:156-161.
    PubMed     Abstract available


  68. KAWAMI N, Takenouchi N, Umezawa M, Hoshino S, et al
    Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
    Digestion. 2017;95:140-145.
    PubMed     Abstract available


    January 2017
  69. OVERBY A, Murayama SY, Michimae H, Suzuki H, et al
    Prevalence of Gastric Non-Helicobacter pylori-Helicobacters in Japanese Patients with Gastric Disease.
    Digestion. 2017;95:61-66.
    PubMed     Abstract available


    December 2016
  70. TSUJIMAE M, Yamashita H, Hashimura H, Kano C, et al
    A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Digestion. 2016;94:240-246.
    PubMed     Abstract available


    January 2016
  71. TAKESHITA E, Sakata Y, Hara M, Akutagawa K, et al
    Higher Frequency of Reflux Symptoms and Acid-Related Dyspepsia in Women than Men Regardless of Endoscopic Esophagitis: Analysis of 3,505 Japanese Subjects Undergoing Medical Health Checkups.
    Digestion. 2016;93:266-71.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: